


CLAIMS

1. Compounds of General Formula 1:



General Formula 1

5 wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C_{1-7} -alkyl, aryl- C_{1-7} -alkyl, or (*E*)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C_{1-7} -alkyl;

10 X represents aryl; aryl- C_{1-7} -alkyl-; aryl-O-; aryl- C_{1-7} -alkyl-O-; R^1 -SO₂NR²-; R^1 -CONR²-; aryl-R⁸-CONR²-; R^1 -NR³CONR²-; R^1 -NR²CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

15 Z represents hydrogen; in case X represents aryl or aryl- C_{1-7} -alkyl Z represents hydrogen, hydroxyl, carboxyl or R^4 -NR⁵CO-; in case X represents R^1 -NR²CO- Z represents hydrogen or C_{1-7} -alkyl; or in case X represents aryl or aryl- C_{1-7} -alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R^4 -NR⁵CO-, aryl or aryl- C_{1-7} -alkyl;

Y represents $-C(R^6)(R^7)(CH_2)_m-$ or $-(CH_2)_mC(R^6)(R^7)-$;

20 m represents the numbers 1 or 2;

n represents the numbers 0 or 1;

R^1 represents aryl or aryl- C_{1-7} -alkyl;

R^2 represents hydrogen; C_{1-7} -alkyl; 2-hydroxyethyl; aryl- C_{1-7} -alkyl; or a saturated carbocyclic ring;

R^3 represents hydrogen or C_{1-7} -alkyl;

R^4 represents hydrogen; C_{1-7} -alkyl; aryl; aryl- C_{1-7} -alkyl; or forms together with R^5 a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R^4 and R^5 are attached as ring atom;

5 R^5 represents hydrogen; C_{1-7} -alkyl; 2-hydroxyethyl; or forms together with R^4 a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R^4 and R^5 are attached as ring atom;


10 R^6 represents hydrogen; C_{1-7} -alkyl; aryl; aryl- C_{1-7} -alkyl; or forms together with R^7 a saturated carbocyclic ring including the carbon atom to which R^6 and R^7 are attached as ring atom;

R^7 represents hydrogen; methyl; or forms together with R^6 a saturated carbocyclic ring including the carbon atom to which R^6 and R^7 are attached as ring atom.

R^8 represents a saturated carbocyclic ring;

15 and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates; as well as their pharmaceutically acceptable salts, solvent complexes, and morphological forms.

2. Compounds of General Formula 2 according to claim 1:



20

General Formula 2

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C_{1-7} -alkyl or aryl- C_{1-7} -alkyl and the substituent in position 6 is methyl or ethyl;

25

X represents aryl; aryl-C₁₋₇-alkyl-; aryl-O-; aryl-C₁₋₇-alkyl-O-; R¹-SO₂NR²-; R¹-CONR²-; aryl-R⁸-CONR²-; R¹-NR³CONR²-; or R¹-NR²CO-;

Z represents hydrogen; in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 1 Z represents hydrogen, hydroxyl or R⁴-NR⁵CO-;

5 n represents the numbers 0 or 1;

R¹ represents aryl or aryl-C₁₋₇-alkyl;

R² represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;


R³ represents hydrogen or C₁₋₇-alkyl;

10 R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom;

15 R⁵ represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; or forms together with R⁴ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom.

R⁸ represents a saturated carbocyclic ring.


3. Compounds of General Formula 3 according to claim 1:



20 wherein n, Y, Z and Py have the meaning given in General Formula 1.

4. Compounds of General Formula 4 according to claim 1:


91



General Formula 4

wherein n , Y , Z and Py have the meaning given in General Formula 1.


5. Compounds of General Formula 5 according to claim 1:



General Formula 5

wherein R^2 , Y , n and Py have the meaning given in General Formula 1.


6. Compounds of General Formula 6 according to claim 1:



General Formula 6

wherein R^4 , R^5 , Y , n and Py have the meaning given in General Formula 1.


7. Compounds of General Formula 7 according to claim 1:



General Formula 7

wherein R^1 , R^2 , Z , Y , n and Z have the meaning given in General Formula 1.

8. Compounds of General Formula 8 according to claim 1:




General Formula 8

92

wherein R^1 , R^2 , n , Y and Py have the meaning given in General Formula 1.


9. Compounds of General Formula 9 according to claim 1:



General Formula 9

5 wherein X , Y , Z , n and Py have the meaning given in General Formula 1.


10. Compounds of General Formula 10 according to claim 1:



General Formula 10

wherein X , Y , Z , n and Py have the meaning given in General Formula 1.


10 11. Compounds of General Formula 11 according to claim 1:



General Formula 11

wherein X , Y , Z , n and Py have the meaning given in General Formula 1.

12. Compounds of General Formula 12 according to claim 1:




General Formula 12

wherein n , Z and Py have the meaning given in General Formula 2.


93

13. Compounds of General Formula 13 according to claim 1:




wherein n, Z and Py have the meaning given in General Formula 2.

5 14. Compounds of General Formula 14 according to claim 1:




wherein R², n and Py have the meaning given in General Formula 2.

15. Compounds of General Formula 15 according to claim 1:



wherein R⁴, R⁵, n and Py have the meaning given in General Formula 2.


16. Compounds of General Formula 16 according to claim 1:



wherein R¹, R², Z, n and Z have the meaning given in General Formula 2.


17. Compounds of General Formula 17 according to claim 1:

94




wherein R^1 , R^2 , n and Py have the meaning given in General Formula 2.

18. Compounds of General Formula 18 according to claim 1:




wherein X, Z and Py have the meaning given in General Formula 2.

19. Compounds of General Formula 19 according to claim 1:




wherein X, Z and n have the meaning given in General Formula 2.

20. Compounds of General Formula 20 according to claim 1:



wherein X, Z and n have the meaning given in General Formula 2.


21. Compounds of General Formula 21 according to claim 1:



95


wherein R¹ and R² have the meaning given in General Formula 2.

22. Compounds of General Formula 22 according to claim 1:




5 wherein R² and n have the meaning given in General Formula 2.

23. Compounds of General Formula 23 according to claim 1:




wherein Z has the meaning given in General Formula 2.

10 24. Compounds of General Formula 24 according to claim 1:



wherein Z has the meaning given in General Formula 2.

25. Compounds of the General Formula 25.



15

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl, aryl-C₁₋₇-alkyl, or (*E*)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C₁₋₇-alkyl;

5 X represents aryl; aryl-O-; aryl-C₁₋₇-alkyl-; R¹-SO₂NR²-; R¹-CONR²-; R¹-NR³CONR²-; R¹-NR²CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

Y represents -C(R⁴)(R⁵)(CH₂)_m- or -(CH₂)_mC(R⁴)(R⁵)-;

10 Z represents hydrogen; in case X represents aryl or aryl-C₁₋₇-alkyl Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-; or in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-, aryl, aryl-C₁₋₇-alkyl;

n represents the numbers 0 or 1;

m represents the numbers 1 or 2;

15 R¹ represents aryl; C₁₋₇-alkyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R² and R³ represent independently hydrogen; C₁₋₇-alkyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

20 R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated carbocyclic ring including the carbon atom to which R⁴ and R⁵ are attached as ring atom;

R⁵ represents hydrogen; methyl; or forms together with R⁴ a saturated carbocyclic ring including the carbon atom to which R⁴ and R⁵ are attached as ring atom;

25 and configurational isomers, optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates; as well as their pharmaceutically acceptable salts, solvent complexes, and morphological forms.

26. The compound according to any one of claims 1 to 25 that is selected from the group consisting of

1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea
1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy- <i>N</i> -propyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro- <i>N</i> -propyl-benzenesulfonamide
1-(2,6-Dimethyl-pyridin-4-yl)-3-[2-(3,3-diphenyl-pyrrolidin-1-yl)-ethyl]-urea
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-methoxy-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-fluoro-benzenesulfonamide
1-(2-{3-[2-Methyl-6-((<i>E</i>)-styryl)-pyridin-4-yl]-ureido}-ethyl)-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide
<i>N</i> -Ethyl-4-methoxy- <i>N</i> -(1-{2-[3-(2-methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
1-{2-[3-(2-Methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide
1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea
<i>N</i> -Ethyl-4-methoxy- <i>N</i> -(1-{2-[3-(2-methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea
<i>N</i> -Ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide
1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-phenethyl-pyridin-4-yl)-urea

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-{2-[2-(4-fluoro-phenyl)-ethyl]-pyridin-4-yl}-urea
1-{2-[3-(2-Methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide
2-(4-Chloro-phenyl)-N-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-ethyl-acetamide
N-Cyclopropyl-N-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide
1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide
1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide
N-Ethyl-N-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide
1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea
N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-ethyl-4-methoxy-benzenesulfonamide
N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-ethyl-4-fluoro-benzenesulfonamide
N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-N-propyl-benzenesulfonamide
4-Bromo-N-ethyl-N-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-N-propyl-benzenesulfonamide
N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-N-methyl-benzenesulfonamide
N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-N-methyl-benzenesulfonamide
N-{4-[(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-sulfamoyl]-phenyl}-acetamide

<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4, <i>N</i> -dimethyl-benzenesulfonamide
4-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-benzenesulfonamide
3,4-Dichloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-4-trifluoromethyl-benzenesulfonamide
5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3-fluoro-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-fluoro-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2,4-difluoro-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3,4-difluoro-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2,6-difluoro-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4, <i>N</i> -diethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-isopropoxy-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-methyl-

benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3-methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-methoxy-2,3,6-trimethyl-benzenesulfonamide
4-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzenesulfonamide
3-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzenesulfonamide
2-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzenesulfonamide
3,4-Dichloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-trifluoromethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3-trifluoromethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-trifluoromethyl-benzenesulfonamide
Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide
5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide
2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2,5-dimethoxy-benzenesulfonamide
5-Bromo- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-methoxy-benzenesulfonamide

<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-methoxy-4-methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3,4-dimethoxy-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3-methoxy-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methyl-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methyl-benzenesulfonamide
4-Chloro- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
3-Chloro- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
2-Chloro- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
3,4-Dichloro- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-

trifluoromethyl-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-trifluoromethyl-benzenesulfonamide
5-Chloro-thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
2,5-Dichloro-thiophene-3-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,5-dimethoxy-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide
<i>N</i> -Ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide
<i>N</i> -Ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-benzenesulfonamide
<i>N</i> -Ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
2-(4-Chloro-phenyl)- <i>N</i> -ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide
2-(3,4-Dichloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-acetamide
2-(4-Chloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-isobutyramide
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide

1-Phenyl-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
2-(4-Chloro-phenyl)- <i>N</i> -ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide
2-(4-Chloro-phenyl)- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide
2-(4-Chloro-phenyl)- <i>N</i> -cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
1-Phenyl-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-methoxy-benzenesulfonamide

27. The compound according to any one of claims 1 to 25 that is selected from the group consisting of

<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-methoxy-phenyl)-acetamide
4-Ethyl-1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy- <i>N</i> -methyl-benzenesulfonamide

<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4, <i>N</i> -dimethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3, <i>N</i> -dimethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2, <i>N</i> -dimethyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-2,3,6, <i>N</i> -tetramethyl-benzenesulfonamide
3-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-benzenesulfonamide
2-Chloro- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-benzenesulfonamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-3-trifluoromethyl-benzenesulfonamide
Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-

3,4-difluoro-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methyl-benzenesulfonamide
<i>N</i> -Cyclopropyl- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethyl-benzenesulfonamide
Thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
2-(3,4-Dichloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-acetamide
1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide
2-(4-Chloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-fluoro-phenyl)- <i>N</i> -methyl-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-2-phenyl-acetamide
2-(3-Chloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -methyl-acetamide
2-(2-Chloro-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-(2-methoxy-phenyl)-acetamide
1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide
1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-phenyl-acetamide

<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-(4-methoxy-phenyl)-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-methoxy-benzamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-3,4-dimethoxy-benzamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-4-fluoro-benzamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-(3-methoxy-phenyl)-acetamide
2-(3,4-Dimethoxy-phenyl)- <i>N</i> -(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-thiophen-2-yl-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-2-(4-fluoro-phenyl)-acetamide
<i>N</i> -(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)- <i>N</i> -ethyl-benzamide
1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide
<i>N</i> -Ethyl- <i>N</i> -(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-phenyl-acetamide
1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide

28. Pharmaceutical compositions containing a compound of any one of claims 1 to 27 and usual carrier materials and adjuvants for the treatment of disorders which are associated with a dysregulation of urotensin II or urotensin II receptors, or disorders associated with vascular or myocardial dysfunction, comprising hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm,

cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.

29. Pharmaceutical compositions containing a compound of any one of claims 1 to 27 and usual carrier materials and adjuvants for the treatment of disorders comprising restenosis after balloon or stent angioplasty, for treatment of cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, or neurodegenerative diseases.

30. The use of one or more compounds of any one of claims 1 to 27 in combination with other pharmacologically active compounds for the treatment of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis, restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia,

Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, or neurodegenerative diseases.

- 5 31. The use of one or more compounds of any one of claims 1 to 30 in combination with other pharmacologically active compounds comprising ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, or peroxisome proliferator activator receptor modulators.
- 10 32. The method of treating a patient suffering from a disorder given in any one of claims 28 to 31 by administering a pharmaceutical composition according to any one of claims 28 and 29.